The core concepts of core binding factor acute myeloid leukemia: current considerations for prognosis and treatment
C Darwish, K Farina, D Tremblay - Blood Reviews, 2023 - Elsevier
Core binding factor acute myeloid leukemia (CBF AML), defined by t (8; 21) or inv (16), is a
subset of favorable risk AML. Despite its association with a high complete remission rate …
subset of favorable risk AML. Despite its association with a high complete remission rate …
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
A Bataller, A Garrido, F Guijarro, G Oñate… - Blood …, 2022 - ashpublications.org
Abstract The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and
management of acute myeloid leukemia (AML) have become fundamental guidelines to …
management of acute myeloid leukemia (AML) have become fundamental guidelines to …
Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse
AS Skou, KL Juul‐Dam, HB Ommen… - British Journal of …, 2021 - Wiley Online Library
Longitudinal molecular measurable residual disease (MRD) sampling after completion of
therapy serves as a refined tool for identification of imminent relapse of acute myeloid …
therapy serves as a refined tool for identification of imminent relapse of acute myeloid …
[HTML][HTML] Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes
S Yu, T Lin, D Nie, Y Zhang, Z Sun, Q Zhang… - Blood cancer …, 2021 - nature.com
We aimed to investigate outcomes of different post-remission treatment (PRT) choices based
on dynamic measurable residual disease (MRD) by multiparameter flow cytometry in …
on dynamic measurable residual disease (MRD) by multiparameter flow cytometry in …
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
J Senapati, M Shoukier… - American journal of …, 2022 - Wiley Online Library
Background Posttherapy measurable residual disease (MRD) positivity in core binding
factor acute myeloid leukemia (CBF‐AML) is associated with shorter relapse‐free survival …
factor acute myeloid leukemia (CBF‐AML) is associated with shorter relapse‐free survival …
Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission
T Konuma, T Kondo, M Masuko, H Shimizu… - Bone marrow …, 2021 - nature.com
Pretransplant measurable residual disease (MRD) has been shown to be associated with
relapse incidence following allogeneic hematopoietic cell transplantation (HCT) for acute …
relapse incidence following allogeneic hematopoietic cell transplantation (HCT) for acute …
[HTML][HTML] MRD-directed and risk-adapted individualized stratified treatment of AML
Y Zhao, H Guo, Y Chang - Chinese Journal of Cancer Research, 2023 - ncbi.nlm.nih.gov
Measurable residual disease (MRD) has been widely recognized as a biomarker for deeply
evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions …
evaluating complete remission (CR), predicting relapse, guiding pre-emptive interventions …
[HTML][HTML] Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT …
W Chen, J Huang, Y Zhao, L Huang, Z Yuan… - Journal of Translational …, 2024 - Springer
Abstract Background Droplet digital PCR (ddPCR) is widely applied to monitor measurable
residual disease (MRD). However, there are limited studies on the feasibility of ddPCR-MRD …
residual disease (MRD). However, there are limited studies on the feasibility of ddPCR-MRD …
[HTML][HTML] How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual …
A Talami, F Bettelli, V Pioli, D Giusti, A Gilioli… - Biomedicines, 2021 - mdpi.com
Acute myeloid leukemia (AML) carrying inv (16)/t (16; 16), resulting in fusion transcript CBFB-
MYH11, belongs to the favorable-risk category. However, even if most patients obtain …
MYH11, belongs to the favorable-risk category. However, even if most patients obtain …
Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t (8; 21) acute myeloid leukemia
W Guo, X Liu, M Wang, J Liu, Y Cao, Y Zheng… - …, 2023 - Taylor & Francis
Objectives To determine the impact of pretransplant measurable residual disease (pre-
MRD) and the efficacy of maintenance therapy in t (8; 21) acute myeloid leukemia (AML) …
MRD) and the efficacy of maintenance therapy in t (8; 21) acute myeloid leukemia (AML) …